Minerva Neurosciences | NERV - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Adma Biologics USD 87.63M 26.24M 2025-12
ALKERMES USD 388.57M 227.88M 2025-12
Alterity Therapeutics Limited AUD 15.77M 9.56M 2023-06
AstraZeneca USD 8.14B 1.08B 2025-09
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Cipla INR 7.96B 39.9M 2025-09
Clal Biotechnology ILS 5.73M 1.71M 2023-12
Compugen USD 90.6M 83.14M 2025-12
CSL USD 2.16B 633M 2025-06
Eli Lilly USD 7.27B 2.52B 2025-12
Esperion Therapeutics USD 92.45M 6.39M 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Grifols EUR 979.78M 334.84M 2024-12
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
J&J USD 19.71B 1.48B 2025-12
Merck USD 18.17B 10.16B 2025-09
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Novartis USD 9.56B 2.9B 2025-09
Novavax USD 240.63M 27.39M 2025-12
Pfizer USD 1.34B 295M 2025-09
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12